Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies

AIDS Reader

Volumn 11, Issue 4, 2001, Pages 209-215+217

  Angel, J B ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Colony stimulating factor; Granulocytemacrophage; HIV 1 immunogen; Immunotherapy; Interleukin 2

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADJUVANT THERAPY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; REVIEW; SINUS TACHYCARDIA; VIRUS REPLICATION;

AIDS VACCINES; CLINICAL TRIALS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0035058439     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. 6/L CD4 cell counts
2. In vivo assessment of antiviral reactivity in chronic HIV infection
3. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
4. Hematologic complications of HIV infection
5. Clinical spectrum of HIV disease
6. The epidemiology of acquired immunodeficiency syndrome malignancies
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
8. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
9. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
10. Natural history of HIV infection in the era of combination antiretroviral therapy
11. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
12. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
13. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
14. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
15. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
16. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
17. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
18. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease
19. Human immunodeficiency virus
20. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
21. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on HIV-related leukopenia: A randomized, controlled clinical study
22. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: Effect on infections, CD4 cell counts and HIV suppression
23. A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analog therapy in AIDS
24. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
25. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection
26. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
27. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial
28. Safety and immunogenicity of REMUNE™in HIV-infected Thai subjects
29. Immunological and virological evaluations of the effects of HAART compared to HAART plus an inactivated HIV immunogen after 32 weeks
30. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of > 300
31. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand
32. T cell recognition of HIV synthetic peptides In a natural infection
33. Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: Correlation with virus burden
34. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
35. Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection
36. Immunopathogenic mechanisms of HIV infection
37. Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients
38. Altered receptor expression and decreased sensitivity of T-cells to the stimulatory cytokines IL-2, IL-7 and IL-12 in HIV infection
39. Granulocyte-macrophage colony-stimulating factor: Potential therapeutic, immunological and antiretroviral effects in HIV infection
40. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha
41. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha
42. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate
43. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow-cultures to synthesis of MHC class II molecules and to augmented antigen presentation function
44. Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus
45. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced nero-tropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex
46. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection
47. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma
48. A pilot study in the use of GM-CSF in human immunodeficiency virus (HIV) infected individuals
49. Replication of human immunodeficiency virus in monocytes: Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine
50. Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody
51. Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages
52. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: A randomized double-blind, placebo-controlled trial
53. Dysregulation of the interleukin-2 receptor alpha- and beta-chain expression in CD4 and CD8 T cells in HIV infection
54. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: A preliminary study
55. Effects of therapy with highly active anti-retroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients
56. Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART
57. Decreased DC95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration
58. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2
59. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load
60. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: A randomized controlled trial
61. 3
62. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active antiretroviral therapy
63. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
64. A model for the selective loss of major histocompatibility complex of self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS)
65. Cellular anti-gp120 cytolytic reactivities in HIV-1 seropositive individuals
66. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
67. Immunization with subunit human inmunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection
68. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients
69. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gpl60 in patients with early human immunodeficiency virus infection
70. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160
71. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120: A randomized, double-blind trial
72. Active immunization of patients with HIV infection: A study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency
73. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults
74. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo-controlled trial
75. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers
76. Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy
77. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells
78. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: Results of a double-blind, adjuvant-controlled, dose-ranging trial
79. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in Incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE™) in human immunodeficiency virus type-1 seropositive subjects
80. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen
81. Enhancement of HIV type 1 antigen-specifc CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen
82. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant
83. Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen
84. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 10(6)/L CD4 cell counts: A randomized controlled trial
85. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell monocytes in aysmptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen
86. Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection
87. Relations among CD4 lymphocyte countnadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study